Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma

Journal of Surgical Oncology

Volumn 112, Issue 2, 2015, Pages 164-172

  Bagante, Fabio ^a   Tran, Thuy B ^b   Postlewait, Lauren M ^c   Maithel, Shishir K ^c   Wang, Tracy S ^d   Evans, Douglas B ^d   Hatzaras, Ioannis ^e   Shenoy, Rivfka ^e   Phay, John E ^f   Keplinger, Kara ^f   Fields, Ryan C ^g   Jin, Linda X ^g   Weber, Sharon M ^h   Salem, Ahmed ^h   Sicklick, Jason K ⁱ   Gad, Shady ⁱ   Yopp, Adam C ^j   Mansour, John C ^j   Duh, Quan Yang ^k   Seiser, Natalie ^k   Solorzano, Carmen C ^l   Kiernan, Colleen M ^l   Votanopoulos, Konstantinos I ^m   Levine, Edward A ^m   Poultsides, George A ^b   Pawlik, Timothy M ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

adrenocortical carcinoma; neutrophil lymphocyte ratio; platelet lymphocyte ratio; prognosis

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; ESTROGEN; GLUCOCORTICOID; MINERALOCORTICOID; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SPECIFIC SURVIVAL; FEMALE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; INCIDENTALOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; AGED; BLOOD; COMORBIDITY; DISEASE FREE SURVIVAL; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; NEUTROPHIL; PREDICTIVE VALUE; PROGNOSIS; THROMBOCYTE; THROMBOCYTE COUNT;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; BLOOD PLATELETS; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84940053128     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23982     Document Type: Article

References (53)

1. Else T, Kim AC, Sabolch A, et al.,: Adrenocortical carcinoma. Endocr Rev 2014; 35: 282-326.
2. Dackiw AP, Lee JE, Gagel RF, et al.,: Adrenal cortical carcinoma. World J Surg 2001; 25: 914-926.
3. Kebebew E, Reiff E, Duh QY, et al.,: Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World J Surg 2006; 30: 872-878.
4. Bovio S, Cataldi A, Reimondo G, et al.,: Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrimol Invest 2006; 29: 298-302.
5. Abdel-Aziz TE, Rajeev P, Sadler G, et al.,: Risk of adrenocortical carcinoma in adrenal tumours greater than 8cm. World J Surg 2015; 39: 1268-1273.
6. Kendrick ML, Lloyd R, Erickson L, et al.,: Adrenocortical carcinoma: Surgical progress or status quo? Arch Surg 2001; 136: 543-549.
7. Gaujoux S, Al-Ahmadie H, Allen PJ, et al.,: Resection of adrenocortical carcinoma liver metastasis: Is it justified? Ann Surg Oncol 2012; 19: 2643-2651.
8. Crucitti F, Bellantone R, Ferrante A, et al.,: The Italian Registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry study group. Surgery 1996; 119: 161-170.
9. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al.,: Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013; 49: 2579-2586.
10. Tran TB, Liou D, Menon VG, et al.,: Surgical management of advanced adrenocortical carcinoma: A 21-year population-based analysis. Am Surg 2013; 79: 1115-1118.
11. Kerkhofs TM, Verhoeven RH, Bonjer HJ, et al.,: Surgery for adrenocortical carcinoma in The Netherlands: Analysis of the national cancer registry data. Eur J Endocrinol 2013; 169: 83-89.
12. Edge SBBD, Compton CC, Fritz AG, et al.,: AJCC cancer staging manual, 7th edition. New York: Springer; 2010.
13. Bilimoria KY, Shen WT, Elaraj D, et al.,: Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer 2008; 113: 3130-3136.
14. Allolio B, Fassnacht M,: Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab 2006; 91: 2027-2037.
15. Canter DJ, Mallin K, Uzzo RG, et al.,: Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: An analysis of the National Cancer Database. Can J Urol 2013; 20: 6915-6921.
16. Fassnacht M, Johanssen S, Fenske W, et al.,: Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95: 4925-4932.
17. Petrelli F, Barni S, Coinu A, et al.,: The modified Glasgow prognostic score and survival in colorectal cancer: A pooled analysis of the literature. Rev Recent Clin Trials 2015.
18. Li C, Wen TF, Yan LN, et al.,: Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma. J Surg Res 2015.
19. Spolverato G, Maqsood H, Kim Y, et al.,: Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies. J Surg Oncol 2015; 111: 868-874.
20. Lee S, Oh SY, Kim SH, et al.,: Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013; 13: 350.
21. Makkouk A, Weiner GJ,: Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res 2015; 75: 5-10.
22. Coussens LM, Zitvogel L, Palucka AK,: Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science 2013; 339: 286-291.
23. Coussens LM, Werb Z,: Inflammation and cancer. Nature 2002; 420: 860-867.
24. Li MX, Liu XM, Zhang XF, et al.,: Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Int J Cancer 2014; 134: 2403-2413.
25. Templeton AJ, McNamara MG, Seruga B, et al.,: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Cancer 2014; 106: 124.
26. Edge SB, Compton CC, Fritz AG, et al.,: AJCC cancer staging manual. New York: Springer; 2010.
27. McMillan DC, Elahi MM, Sattar N, et al.,: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-69.
28. McMillan DC, Wotherspoon HA, Fearon KC, et al.,: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995; 170: 319-322.
29. Goransson J, Jonsson S, Lasson A,: Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol 1996; 22: 607-617.
30. Chen J, Wu W, Zhen C, et al.,: Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer. Oncol Lett 2013; 6: 43-48.
31. Nielsen HJ, Christensen IJ, Sorensen S, et al.,: Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 colorectal cancer study group. Ann Surg Oncol 2000; 7: 617-623.
32. Fujita T, Hara A, Yamazaki Y,: The value of acute-phase protein measurements after curative gastric cancer surgery. Arch Surg 1999; 134: 73-75.
33. Reitter EM, Ay C, Kaider A, et al.,: Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. Clin Exp Immunol 2014; 177: 253-260.
34. Imrie CW,: Host systemic inflammatory response influences outcome in pancreatic cancer. Pancreatology 2015.
35. Proctor MJ, Morrison DS, Talwar D, et al.,: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 2011; 47: 2633-2641.
36. Lai Q, Castro Santa E, Rico Juri JM, et al.,: Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2014; 27: 32-41.
37. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al.,: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23: 265-273.
38. Ertas IE, Gungorduk K, Akman L,: et al.: Can preoperative neutrophil: Lymphocyte and platelet:lymphocyte ratios be used as predictive markers for lymph node metastasis in squamous cell carcinoma of the vulva? Eur J Obstet Gynecol Reprod Biol 2013; 171: 138-142.
39. Balkwill F, Mantovani A,: Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539-545.
40. Wiemann B, Starnes CO,: Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther 1994; 64: 529-564.
41. Hanahan D, Weinberg RA,: Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
42. Hanahan D, Coussens LM,: Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
43. Ruffell B, Affara NI, Coussens LM,: Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012; 33: 119-126.
44. Beatty GL, Chiorean EG, Fishman MP, et al.,: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-1616.
45. Paramanathan A, Saxena A, Morris DL,: A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 2014; 23: 31-39.
46. Templeton AJ, Ace O, McNamara MG, et al.,: Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1204-1212.
47. Szkandera J, Stotz M, Eisner F, et al.,: External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS ONE 2013; 8: 78225.
48. Teramukai S, Kitano T, Kishida Y, et al.,: Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009; 45: 1950-1958.
49. Ulich TR, del Castillo J, Guo K, et al.,: The hematologic effects of chronic administration of the monokines tumor necrosis factor, interleukin-1, and granulocyte-colony stimulating factor on bone marrow and circulation. American J Pathol 1989; 134: 149-159.
50. Alexandrakis MG, Passam FH, Moschandrea IA, et al.,: Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-140.
51. Zhou X, Du Y, Huang Z, et al.,: Prognostic value of PLR in various cancers: A meta-analysis. PLoS ONE 2014; 9: 101119.
52. Mikahaylova IV, Kuulasmaa T, Jaaskelainen J, et al.,: Tumor necrosis factor-alpha regulates steriodogenesis, apoptosis, and cell viabiilty in the human adrenocortical cell line NCI-H295R. Endocrinology 2007; 148: 386-392.
53. de Fraipont F, El Atifi M, Gicquel C, et al.,: Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J Clin Endocrinol Metab 2000; 85: 41-473.